Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04154501 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

A Phase 1 study of Pain and Chronic Pain, sponsored by Centrexion Therapeutics.

Completed
Registry status
Phase 1
Development phase
68
Enrollment target
1
Study location

NCT04154501 is a Phase 1 study of Pain and Chronic Pain that has completed, run by Centrexion Therapeutics. The registered enrollment target is 68 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04154501, a Phase 1 study of Pain and Chronic Pain, has completed, sponsored by Centrexion Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.

Interventions

  • OTHER Other: Placebo
  • DRUG CNTX-6016

Study Locations (1)

Kansas

  • Altasciences Clinical Research - Overland Park

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2018-12-04
Est. Completion 2019-08-26
Phase Phase 1

Sponsor

Centrexion Therapeutics

12 total trials

What the Registry Record Tells You About NCT04154501

The ClinicalTrials.gov registry entry for NCT04154501 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (78% lower). The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Other: Placebo is the first listed.

NCT04154501 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT04154501 about?

NCT04154501 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects". A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.

What is the current status of trial NCT04154501?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2018-12-04. Estimated completion is 2019-08-26.

What conditions does trial NCT04154501 study?

This clinical trial studies the following conditions: Pain, Chronic Pain, Nociceptive Pain.

What interventions are being tested in trial NCT04154501?

The interventions under investigation include: Other: Placebo (OTHER), CNTX-6016 (DRUG).

Who is sponsoring clinical trial NCT04154501?

This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04154501 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.